专利号:US-2024400576-A1 优先权日:2021-09-03 标 题:Nitrogen-containing derivatives of salinomycin, synthesis and uses thereof 发明人:RODRIGUEZ RAPHAËL; CZERWONKA DOMINIKA; ANTOSZCZAK MICHAL; HUCZYNSKI ADAM 权利人:CENTRE NAT RECH SCIENT; INST CURIE; INST NAT SANTE RECH MED; ADAM MICKIEWICZ UNIV 摘要:The present invention relates to nitrogen-containing derivatives of salinomycin having the formula (I), as well as pharmaceutically acceptable salt thereof, and synthesis and uses thereof, in particular for the treatment and/or prevention of cancer including for preventing cancer metastasis and/or for preventing cancer recurrence and/or for decreasing resistance to a chemotherapy in a subject.
专利号:US-2025250280-A1 优先权日:2021-09-03 标 题 :Nitrogen-containing derivatives of narasin, synthesis and uses thereof 发明人:RODRIGUEZ RAPHAËL; CAÑEQUE TATIANA; MÜLLER SEBASTIAN; ANTOSZCZAK MICHAL 权利人:CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; INST CURIE 摘要:The present invention relates to nitrogen-containing derivatives of narasin having the formula (I), as well as synthesis and uses thereof, in particular for the treatment and/or prevention of cancer. Also disclosed are medicaments including the nitrogen-containing derivatives of narasin, which include medicaments for preventing cancer metastasis and/or for preventing cancer recurrence and/or for decreasing resistance to a chemotherapy in a subject.
专利号:WO-2023031399-A1 优先权日:2021-09-03 标题 :Iron-activable nitrogen-containing derivatives of salinomycin and narasin, synthesis and use for the treatment of cancers
专利号:WO-2023031402-A1 优先权日:2021-09-03 标 题 :Nitrogen-containing derivatives of salinomycin, synthesis and uses thereof
专利号:WO-2023031362-A1 优先权日:2021-09-03 标题:Nitrogen-containing derivatives of narasin, synthesis and uses thereof
专利号:EP-4396189-B1 优先权日:2021-09-03 标题 :Iron-activable nitrogen-containing derivatives of salinomycin and narasin, synthesis and use for the treatment of cancers 发明人:RODRIGUEZ RAPHAËL; CAÑEQUE TATIANA; MÜLLER SEBASTIAN; ANTOSZCZAK MICHAL 权利人:CENTRE NAT RECH SCIENT; INST CURIE; INST NAT SANTE RECH MED
1: Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA. Barasertib,(AZD1152)a small molecule Aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo. Mol Cancer Ther. 2016 Aug 5. pii: molcanther.0298.2016. [Epub ahead of print] doi: 10.1002/jlcr.3376. doi: 10.1007/s00277-016-2670-6. Epub 2016 Apr 19. doi: 10.1007/s12035-015-9139-9. Epub 2015 Mar 11. doi: 10.1111/bjh.13333. Epub 2015 Feb 26. doi: 10.1007/s13277-014-2664-8. Epub 2014 Oct 3. doi: 10.1016/j.clml.2013.03.019. Epub 2013 Jun 10. 8: Kantarjian HM, Martinelli G, Jabbour EJ, Quintás-Cardama A, Ando K, Bay JO, Wei A, Gröpper S, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK, Giagounidis A; SPARK-AML1 Investigators. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013 Jul 15;119(14):2611-9. doi: 10.1002/cncr.28113. Epub 2013 Apr 19. 9: Ma YX, Li XZ. [Effect of aurora kinase B inhibitor AZD1152 in the treatment of cisplatin-resistant ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 2013 Jan;48(1):46-50. Chinese. doi: 10.1007/s00404-013-2719-x. Epub 2013 Feb 7. doi: 10.1007/s00280-012-1939-2. Epub 2012 Aug 4.
合成参考文献
参考文献:10.1124/mol.119.115964 摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.